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ABSTRACT
Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors
in patients with type 2 diabetes have shown that they reduce three-point major adverse
cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a com-
posite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in
type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease
or advanced renal disease. HF is a major determinant of the prognosis of diabetes
patients. Although HF with low ejection fraction can be effectively treated with antihyper-
tensive drugs, these treatments do not reduce mortality in HF patients with preserved
ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dys-
function, perivascular fibrosis and stiffness of cardiomyocytes, defined as “cardiomyopathy”.
Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection
fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibi-
tors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia,
volume overload, hypertension and cardiac inflammation. In the final part of the present
review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2
inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low
nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine
signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism
as a result of ketone body production. Investigations of the beneficial effects of SGLT2
inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried
out in preclinical and clinical studies.
INTRODUCTION
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a new
class of oral glucose-lowering drug that inhibits renal glucose
reabsorption, thereby increasing urinary glucose loss and caus-
ing osmotic diuresis in people with and without diabetes.
SGLT2 inhibitor administration causes a urinary loss of 60–
100 g glucose per day, which induces a negative energy balance,
resulting in a significant change in whole-body energy
metabolism1–7. Plasma glucose and insulin concentrations are
significantly reduced in type 2 diabetes patients by treatment
with SGLT2 inhibitors, and those are associated with significant
improvements in both insulin resistance and insulin secretion8–
11. In addition, SGLT2 inhibitors increase glucagon secretion
through direct stimulation of pancreatic a-cells12. As a result,
they reduce hepatic triglyceride synthesis, fat deposition in the
liver and serum triglyceride concentration, and increase hepatic
ketone body production5–7,11. Furthermore, the greater urinary
glucose loss increases urinary uric acid excretion, resulting in a
reduction in serum uric acid concentration13. Therefore, SGLT2
inhibitor treatment has beneficial effects on multiple athero-
genic risk factors in patients with type 2 diabetes. SGLT2 inhi-
bitors also have hemodynamic effects: they increase urinary
water excretion and sodium loss, resulting in reductions in
bodyweight, and both systolic and diastolic blood pressure14–19.
These metabolic and hemodynamic effects of SGLT2 inhibitors
have already been extensively reviewed20.
Almost all the cardiovascular risk factors commonly found
in patients with metabolic syndrome are significantly
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ameliorated by treatment with ipragliflozin, as shown in a
pooled analysis of six Japanese phase II and III randomized
controlled trials (RCTs)21. These beneficial effects on hemody-
namic and metabolic parameters might also protect against the
progression of atherogenic cardiovascular disease (CVD) in
type 2 diabetes patients. Indeed, SGLT2 inhibitor treatment in
type 2 diabetes patients with high cardiovascular risk consis-
tently has reduced the incidence of hospitalization for heart fail-
ure (HHF), cardiovascular (CV) death and a renal composite
outcome (RCO) in four multicenter RCTs22–27.
Interestingly, major multicenter clinical RCTs found that glu-
cagon-like peptide-1 receptor agonists also effectively protect
against not only cardiovascular events, but also progression of
renal disease, which is consistent with the results found in the
use of SGLT2 inhibitors. In the Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular Outcome Results (LEA-
DER) trial, liraglutide treatment for 3.8 years significantly
reduced major adverse cardiovascular events (MACE), includ-
ing cardiovascular death, non-fatal myocardial infarction and
non-fatal stroke with a hazard ratio (HR) of 0.87 (P < 0.01)
compared with placebo28. In the Trial to Evaluate Cardiovascu-
lar and Other Long term Outcomes with semaglutide in
patients with Type 2 Diabetes (SUSTAIN 6), semaglutide treat-
ment for 2.1 years showed a HR of 0.74 for MACE
(P < 0.02)29. However, the Exenatide Study of Cardiovascular
Event Lowering (EXSCEL) showed a HR for MACE that did
not reach the threshold for demonstrated superiority versus pla-
cebo for the entire trial30. Taken together, it appears that
among patients with established CVD, both liraglutide and
semaglutide might provide cardiovascular benefits, but exe-
natide is less certain in regard to clinical benefits. Furthermore,
protection against HHF has not been reported to be statistically
significant with the use of any glucagon-like peptide-1 receptor
agonists, which is entirely different from the results of treat-
ment with SGLT2 inhibitors. The mechanisms to explain those
differences between two types of drugs have not been exten-
sively compared in the previous studies. Based on the evidence
from recent major multicenter clinical RCTs, both SGLT2 inhi-
bitors and glucagon-like peptide-1 receptor agonists have been
used as medicines to effectively protect not only cardiovascular
events28,29, but also progression of renal disease29,31 in the 2019
European Society of Cardiology guidelines on diabetes, predia-
betes and cardiovascular disease32.
In the present review, we discuss several recent lines of evi-
dence, which show that the use of SGLT2 inhibitors effectively
prevents event rates of MACE, CV death, HHF and renal out-
comes in type 2 diabetes patients with high CV risk or a his-
tory of advanced CVD or advanced renal disease. Finally, we
represent a paradigm shift in the prevention of heart failure in
type 2 diabetes patients to improve their life prognosis. We
then summarize the subcellular biochemical and molecular
mechanisms involved in the development of heart failure with
preserved ejection fraction (HFpEF), and discuss the
effectiveness of SGLT2 inhibitors for the treatment of HFpEF
and HF with low ejection fraction (HFrEF) in diabetes patients.
LARGE MULTICENTER PLACEBO-CONTROLLED RCTS OF
THE USE OF SGLT2 INHIBITORS FOR THE PREVENTION
OF CARDIORENAL DISEASES
Reduction of the incidence of MACE
Four major multicenter RCTs of the use of SGLT2 inhibitors
for the prevention of cardiorenal outcomes in diabetes patients
were published between 2015 and 2019. Excellent reviews of
the relationship between patient characteristics and cardiovascu-
lar outcomes in these four trials, and the mechanisms of these
cardiovascular benefits have already been published33–35, and
the characteristics of the participants in the four trials are
shown in Table 1. These trials were the Empagliflozin Cardio-
vascular Outcome Event Trial in Type 2 Diabetes Mellitus
Patients (EMPA-REG OUTCOME) trial22–24, which involved
the administration of 10 or 25 mg empagliflozin daily; the
Canagliflozin Cardiovascular Assessment Study (CANVAS)25,
which involved the administration of 100 mg or 300 mg cana-
gliflozin daily; the Dapagliflozin Effect on Cardiovascular
Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-
TIMI 58) trial26, which involved the administration of 10 mg
dapagliflozin daily; and the Canagliflozin and Renal Events in
Diabetes with Established Nephropathy Clinical Evaluation
(CREDENCE) trial27, which involved the administration of
100 mg canagliflozin daily.
The primary end-points of each trial were evaluated after a
mean follow-up period of 2.4–4.2 years. The baseline character-
istics of the recruited patients are summarized in Table 1. They
had a mean glycated hemoglobin of 8.1–8.3%, and renin–an-
giotensin–aldosterone system inhibitors and statins were used
in >75% and 80% of patients, respectively. Reductions in gly-
cated hemoglobin, bodyweight and systolic/diastolic blood pres-
sure of 0.24–0.58%, 0.8–1.8 kg and 3–4 mmHg/0.36–
1.39 mmHg were achieved, respectively. These drug effects were
similar among the four trials of SGLT2 inhibitors, but there
were clear differences in some of the baseline cardiorenal risk
factors in the diabetes patients in these trials (Table 2).
Almost all the participants (99%) in the EMPA-REG OUT-
COME trial had a previous history of CVD, 40% had a mean
urinary albumin-to-creatinine ratio (UACR) above the microal-
buminuric threshold, and 26% had an estimated glomerular
filtration rate (eGFR) <60 mL/min/1.73 m2. However, the par-
ticipants in the CREDENCE trial had the most advanced renal
disease of the four clinical trials, with 99.3% having a mean
UACR above the microalbuminuric threshold, and 60% having
an eGFR < 60 mL/min/1.73 m2. In contrast, the participants in
the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis
in Myocardial Infarction 58 (DECLARE-TIMI 58) trial had the
lowest cardiorenal risk, with just 41% having a previous history
of CVD, 30% having a mean UACR above the microalbumin-
uric threshold and 7% having an eGFR <60 mL/min/1.73 m2.
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A total of 66% of the participants in CANVAS had a previous
history of CVD (65.6%), 30.2% had a mean UACR above the
microalbuminuric threshold and 20.1% had an eGFR <60 mL/
min/1.73 m2, showing that they had a prevalence of cardiorenal
comorbidities between the EMPA-REG OUTCOME and
DECLARE-TIMI 58 trials.
The EMPA-REG OUTCOME trial of 7,020 type 2 diabetes
patients showed that empagliflozin administration was associ-
ated with a 14% lower incidence (P = 0.04) of MACE after a
mean of 3.1 years (Table 3). Similarly, in the CREDENCE trial,
patients treated with 100 mg canagliflozin daily had a 20%
lower incidence (P = 0.01) of MACE than those administering
the placebo after a median of 2.62 years (Table 3). However, in
the CANVAS study cohort, 10,142 type 2 diabetes patients
were assigned to receive canagliflozin (100 mg, with the option
to increase this to 300 mg, daily) or placebo for a median of
2.4 years (Table 3). The reduction in the incidence of MACE
in the canagliflozin group versus the placebo group was not sig-
nificant (HR 0.86, P = 0.08). Finally, the DECLARE-TIMI 58
trial included 17,160 type 2 diabetes patients who were followed
for a median of 4.2 years. The patients in that trial had lower
CVD risk and were at an earlier stage of CKD than those in
the CREDENCE trial, the EMPA-REG OUTCOME trial and
CANVAS, as shown in Table 2. Also in the DECLARE-TIMI
58 trial, the reduction in the incidence of MACE in the dapa-
gliflozin group was not significantly different from that in the
Table 1 | Baseline characteristics of the type 2 diabetes patients in the four clinical trials in which the preventive effects of sodium–glucose
cotransporter 2 inhibitors against cardiorenal events were investigated
Study EMPA-REG OUTCOME CANVAS DECLARE-TIMI 58 CREDENCE
Patients enrolled (n) 7,020 10,142 17,160 4,401
Drug Empagliflozin Canagliflozin Dapagliflozin Canagliflozin
Dose 10 or 25 mg 100 or 300 mg 10 mg 100 mg
Median duration of follow up 3.1 years 2.4 years 4.2 years 2.62 years
Mean baseline HbA1c 8.1% 8.2% 8.3% 8.3%
Mean duration of diabetes NA 13.5 years 11 years 15.8 years
Baseline RAASI use 81% ≥80% 81% 100%
Baseline statin use 77% 75% 75% NA
HbA1c reduction 0.24% 0.58% 0.42% 0.25%
BW reduction 1.79 kg 1.6 kg 1.8 kg 0.8 kg
Blood pressure (mmHg) reduction (SBP/DBP) 2.96/0.36 3.93/1.39 2.7/0.7 3.30/0.95
BW, bodyweight; CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established
Nephropathy Clinical Evaluation; DBP, diastolic blood pressure; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in
Myocardial Infarction 58, EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HbA1c, gly-
cated hemoglobin; NA, not available; RAASI, renin–angiotensin–aldosterone system inhibitor; SBP, systolic blood pressure.
Table 2 | Previous history of cardiorenal risk factors and events in the type 2 diabetes patients enrolled in the four clinical trials of sodium–glucose
cotransporter 2 inhibitors
Study EMPA-REG OUTCOME CANVAS DECLARE-TIMI 58 CREDENCE
Mean eGFR (mL/min/1.73 m2) 74 76.5 85.2 56.2
eGFR (mL/min/1.73 m2)
<60 25.9% 20.1% 7.4% 59.8%
≥60 74.1% 79.9% 92.6% 40.2%
UACR (mg/gCr)
<30 59.4% 69.8% 67.9% 0.7%
30–300 28.7% 22.6% 23.4% 11.3%
>300 11.0% 7.6% 6.8% 88%
Micro- and macroalbuminuria 39.7% 30.2% 30.2% 99.3%
Previous history of CVD 99.2% 65.6% 41% 50%
Previous history of HF 10% 14.8% 10% 14.8%
Existence of multiple CVD risks NA Only two CVD risk factors (≥50 years) 59% NA
CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clini-
cal Evaluation; CVD, cardiovascular disease; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58;
eGFR, estimated glomerular filtration rate; EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus
Patients; HF, heart failure; NA, not available; UACR, urinary albumin-to-creatinine ratio.
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placebo group (HR 0.93, P = 0.17; Table 3). Therefore, the
findings of the major RCTs suggest that SGLT2 inhibitor treat-
ment is more likely to prevent MACE in patients with a higher
CVD risk, a previous history of CV events and/or advanced
renal disease.
Reduction in the incidence of RCOs
As shown in Table 4, the RCOs were defined as: (i) a sustained
reduction of ≥40% in eGFR to <60 mL/min/1.73 m2; (ii) a
diagnosis of end-stage renal disease and dialysis for ≥90 days;
or (iii) kidney transplant or a sustained eGFR of <15 mL/min/
1.73 m2; with the addition of (iv) renal disease-related death in
the DECLARE-TIMI 58 trial26. There was a HR for this RCO
of 0.53 (95% confidence interval [CI] 0.43–0.66) in the dapagli-
flozin group versus the placebo group. In CANVAS25, there
was a HR of 0.60 (95% CI 0.47–0.77) for the RCO in the cana-
gliflozin group versus the placebo group, in the EMPA-REG
OUTCOME trial23,24, the equivalent HR was 0.54 (95% CI
0.47–0.75) for the empagliflozin group versus the placebo
group, and in the CREDENCE trial, it was 0.66 (95% CI 0.53–
0.81) for the canagliflozin group versus the placebo group.
These data showed that there were similar reductions in the
risk of the RCO after treatment with various SGLT2 inhibitors,
although there were some differences in the definitions of the
RCO used among the four RCTs. However, we might add the
following evidence that the absolute renal event rates were
highest in the CREDENCE trial27, probably because the partici-
pants had the highest prevalence of comorbidities associated
with advanced renal dysfunction and micro-/macroalbuminuria
at baseline among the four trials.
Reductions in the incidences of HHF and CV death
The absolute incidences per 1,000 patient-years of HHF and
CV death were significantly less after treatment with each of
the SGLT2 inhibitors (HR 0.66–0.83) than in the control
groups. The reductions in relative risk and the absolute event
rate for HHF and CV death were greater in the EMPA-REG
OUTCOME and CREDENCE trials than in the DECLARE-
TIMI 58 trial and CANVAS (Table 5). However, the reduction
in the relative risk of HHF alone was similar among the four
trials (HR 0.61–0.73). Surprisingly, the reduction in HHF was
evident after approximately 6 months of treatment with empa-
gliflozin, suggesting that this effect might be independent of
long-term improvements in cardiovascular risk factors.
Comparison of the cardiorenal protection provided by SGLT2
inhibitors and other glucose-lowering drugs
The cardiorenal protective effects of SGLT2 inhibitor treatment
have been studied in real-world clinical practice. In the large
Comparative Effectiveness of Cardiovascular Outcomes in New
Users of SGLT2 inhibitors observational study (CVD-REAL)36,
the addition of an SGLT2 inhibitor was associated with reduc-
tions in the risks of all-cause death and HHF, regardless of the
presence or absence of pre-existing CVD, compared with the
use of other glucose-lowering drugs. Similarly, in the CVD-
REAL2 study37, which was carried out with a variety of patients
across a number of countries, the initiation of a different
SGLT2 inhibitor was associated with reductions in the risks of
CV events, including CV death (HR 0.52), HHF (HR 0.60),
myocardial infarction (HR 0.81) and stroke (HR 0.68). Finally,
CVD-REAL3 study38 aimed to determine the effects of SGLT2
inhibitors on the progression of renal dysfunction in type 2 dia-
betes patients with or without CKD, in routine clinical practice.
The results showed that the initiation of SGLT2 inhibitor therapy
in type 2 diabetes patients is associated with a smaller decline in
kidney function and a lower incidence of a composite of renal
events than the initiation of other glucose-lowering drugs.
PREVENTION OF HEART FAILURE IN DIABETES
PATIENTS IN THE TREATMENT WITH SGLT2
INHIBITORS
Heart failure in diabetes
The current American College of Cardiology/American Heart
Association guidelines define heart failure (HF) as a complex
clinical syndrome39. HF is a major determinant of the progno-
sis of patients with diabetes mellitus. It is generally accepted
that the prevalence of HF in diabetes is twice as high in men
and fivefold as high in women with diabetes compared with
Table 3 | Reductions in the incidence of major adverse cardiovascular events in type 2 diabetic patients induced by sodium–glucose
cotransporter 2 inhibitors
Study MACEs (per 1,000 patient-years)
SGLT2 inhibitor Placebo Hazard ratio (95% CI) P-value
DECLARE-TIMI 58 22.6 24.2 0.93 (0.84–1.03) 0.17
CANVAS 26.9 31.5 0.86 (0.75–0.97) 0.08
EMPA-REG OUTCOME 37.4 43.9 0.86 (0.74–0.99) 0.04
CREDENCE 38.7 48.7 0.80 (0.67–0.95) 0.01
CANVAS, Canagliflozin Cardiovascular Assessment Study; CI, confidence interval; CREDENCE, Canagliflozin and Renal Events in Diabetes with Estab-
lished Nephropathy Clinical Evaluation; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58;
EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; MACEs, major adverse cardiovascular
events; SGLT2, sodium–glucose cotransporter 2.
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age-matched non-diabetic individuals. In addition, older adult
type 2 diabetes patients have a 1.3-fold greater risk of develop-
ing HF than age-matched non-diabetic individuals40,41. Further-
more, it has been reported that patients with diabetic
glomerulosclerosis, but without major coronary artery disease,
cardiac hypertrophy or valvular heart disease develop HF,
which has been defined as a novel type of cardiomyopathy42,43.
Therefore, it is possible that poor long-term glycemic control
puts patients at a higher risk of developing not only diabetic
retinopathy and nephropathy, but also cardiac microvascular
complications with interstitial and perivascular fibrosis, and
myocardial cell death, which are significant risk factors for the
development of HF in diabetes44.
HF with preserved ejection fraction in diabetes
HF can be classified into three types, the first two of which are
HFrEF (ejection fraction [EF] <40%) and HFpEF (EF ≥50%).
Values of EF of 40–49% are defined as midrange. HFpEF is
clinically characterized by poor diastolic function, and the wider
clinical characteristics of patients with HFpEF are listed in Fig-
ure 139,45,46. This type of HF is reported to be highly prevalent
in patients with hypertension, diabetes, obesity, metabolic syn-
drome or chronic kidney disease47. It has also been shown that
multiple parameters associated with high diastolic left
ventricular stiffness negatively correlate with glycated hemoglo-
bin in type 2 diabetes patients, without evidence of abnormal
wall movement or systolic ejection fraction46.
The significance of diabetic microvascular complications for
the risk of HF in diabetes has also been studied. In the Can-
desartan in Heart Failure: Assessment of Resolution in Mortal-
ity and Morbidity (CHARM) trial48, the risks of CV death and
HHF were studied in a population containing patients with
HFrEF or HFpEF and with or without diabetes. The results
showed that diabetes patients had higher risks of CV death and
HHF than patients without diabetes. Furthermore, the incidence
of HHF in diabetes patients was reported to be almost twice
that of non-diabetic patients, irrespective of the presence of
either HFpEF or HFrEF. In addition, the prognosis of diabetes
with or without microangiopathy was compared with that of
non-diabetic patients, all of whom had HFpEF, in the Treat-
ment of Preserved Cardiac Function Heart Failure with an
Aldosterone Antagonist Trial (TOPCAT)49. The cumulative
incidences of HHF and CV death were significantly higher in
diabetes patients with any type of microvascular complication
than in non-diabetic or diabetes patients without microangiopa-
thy. These results suggest that the existence of microvascular
complications in diabetes patients with HFpEF might increase
the risks of both CV death and HHF.
Table 4 | Reductions in the incidences of composite renal-specific outcomes in type 2 diabetic patients induced by sodium–glucose
cotransporter 2 inhibitors
Study Event rates of a composite renal outcome (per 1,000 person-years)
SGLT2 inhibitor Placebo Hazard ratio (95% CI) P-value
DECLARE-TIMI 58 3.7 7 0.53 (0.43–0.66) <0.001
CANVAS 5.5 9 0.60 (0.47–0.77) <0.001
EMPA-REG OUTCOME 6.3 11.5 0.54 (0.40–0.75) <0.001
CREDENCE 28.7 43.7 0.66 (0.53–0.81) P < 0.001
CANVAS, Canagliflozin Cardiovascular Assessment Study; CI, confidence interval; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established
Nephropathy Clinical Evaluation; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58; EMPA-REG
OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; SGLT2, sodium–glucose cotransporter 2.
Table 5 | Reductions in the incidences of hospitalization for heart failure and cardiovascular death or hospitalization for heart failure in type 2
diabetes patients induced by sodium–glucose cotransporter 2 inhibitors
Study Event rates for HHF and CV death (per 1,000 patient-years) Event rates for HHF (per 1,000 patient-years)
SGLT2 inhibitor Placebo Hazard ratio
(95% CI)
P-value SGLT2 inhibitor Placebo Hazard ratio
(95% CI)
P-value
DECLARE-TIMI 58 12.2 14.7 0.83 (0.73–0.95) 0.005 6.2 8.5 0.73 (0.61–0.88) 0.0008
CANVAS 16.3 20.8 0.78 (0.67–0.91) 0.0015 5.5 8.7 0.67 (0.52–0.87) 0.02
EMPA-REG OUTCOME 19.7 30.1 0.66 (0.55–0.79) <0.001 9.4 14.5 0.65 (0.50–0.85) 0.002
CREDENCE 31.5 45.4 0.69 (0.57–0.83) <0.001 15.7 25.3 0.61 (0.47–0.80) 0.00001
CANVAS, Canagliflozin Cardiovascular Assessment Study; CI, confidence interval; CREDENCE, Canagliflozin and Renal Events in Diabetes with Estab-
lished Nephropathy Clinical Evaluation; CV, cardiovascular; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial
Infarction 58; HHF, hospitalization for heart failure; SGLT2, sodium–glucose cotransporter 2.
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Mechanisms of progression of HFpEF in diabetes
As shown in Figure 2, type 2 diabetes patients mostly fit into
two categories with regard to their progression to HF. One cat-
egory comprises type 2 diabetes patients with visceral obesity,
and insulin resistance, hyperinsulinemia, lipid abnormalities
and/or hypertension, who are at higher risk of developing acute
coronary syndrome. Once these patients develop acute coronary
syndrome, they might also develop acute or chronic left ven-
tricular systolic dysfunction, which is classified as HFrEF45.
However, obesity and type 2 diabetes might also lead to
HFpEF, which is induced by an increase in cardiac pre-load,
developing because of volume overload due to plasma volume
expansion. Furthermore, in such patients, insulin resistance and
pro-inflammatory cytokines released from hypertrophied vis-
ceral adipocytes cause arterial stiffness, endothelial dysfunction
in arterioles, and a reduction in capillary density systemically
and in the heart, which results in an increase in cardiac after-
load50–52. These pathophysiological states are highly prevalent
in obese type 2 diabetes patients. The obesity-induced accumu-
lation of cardiovascular risk factors has been studied in pigs fed
a high-fat diet and in which hypertension was induced by renal
artery embolization, over a 6-month period. These animals
showed systemic inflammation, greater myocardial superoxide
production, greater endothelial nitric oxide synthase (eNOS)
uncoupling and lower nitric oxide production, and an impair-
ment in endothelial-dependent vasodilatation in small coronary
arteries53,54.
The second category includes patients with long-standing
type 2 diabetes complicated by the presence of severe diabetic
nephropathy and/or retinopathy, and type 1 diabetes patients
with poor long-term glycemic control. This second group of
patients are characterized by diffuse narrowing and heavy scle-
rosis of distal coronary arteries, perivascular fibrosis, the deposi-
tion of a large amount of extracellular matrix, and the
formation of advanced glycation end-products in cardiac mus-
cle and intracardiac vascular walls, without major coronary
artery stenosis. These changes are characteristic of “diabetic car-
diomyopathy”42–44.
A new strategy for the treatment of HFrEF using SGLT2
inhibitors
Studies of a number of drugs, such as angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, b-blockers,
mineralocorticoid receptor antagonists, diuretics and sacubitril/
valsartan (a combination of a neprilysin inhibitor and an angio-
tensin receptor blocker) have shown that they reduce the risk
of mortality in patients with HFrEF32,55,56. Neprilysin is a zinc-
dependent metalloprotease that cleaves peptides at the amino
side of hydrophobic residues, thereby inactivating several pep-
tide hormones, including glucagon, brain natriuretic peptide
and bradykinin. Therefore, the beneficial clinical effects of the
neprilysin inhibitor, sacubitril, might relate to its inhibition of
vasoactive peptide degradation. In addition, the efficacy of
SGLT2 inhibitors for the prevention of HHF has been studied
in 4,744 patients with symptoms of HF, New York Heart Asso-
ciation (NYHA) stage II–IV and EF ≤40%. The participants
were treated with 10 mg dapagliflozin or placebo once daily for
a median of 18.2 months57, and deterioration in HF occurred
in 16.3% of those in the dapagliflozin group, but 21.2% of those
in the placebo group (HR 0.74, 95% CI 0.65–0.85; P < 0.001).
This protective effect of dapagliflozin was similar in patients
with or without diabetes.
The use of SGLT2 inhibitors for the treatment of patients with
type 2 diabetes and HFpEF
HFpEF is considered to be an entirely separate entity to HFrEF
and is present in nearly 50% of patients with HHF. Multicenter
RCTs have not shown a reduction in the incidence of mortality
1. HF is classified into three types, on the basis of left ventricular ejection fraction: HFrEF: LVEF <40%,
HFmrEF: LVEF 40–49%, and HFpEF: LVEF ≥50%.
Patients with HFpEF exhibit signs of heart failure, namely dyspnea, fatigue, fluid retention, and
excercise intolerance.
Patients with HFpEF have high circulating BNP (≥35 pg/mL) and NT-proBNP (≥125 pg/mL)
concentrations. 
At least one additional criterion: either relevent structrual heart disease (left ventricular hypertrophy
and/or left arterial enlargement) or diastolic dysfunction
Characteristics of impaired left ventricular dysfunction, identified using CMR or TTE
Early-to-late transmitral flow ratio (E/A): low
Deceleration time (DecT): high
End-diastolic volume (EDV)/body surface area: low
Normalized peak LV filling rate (pLVFR)/body surface area: low
Early transmitral flow velocity to septal velocity ratio (E/e’): high











Figure 1 | Classification of 3 type of heart failure and clinical diagnosis of HFpEF Characteristics of patients with heart failure with preserved
ejection fraction(HFpEF) were shown in this figure. BNP, brain natriuretic peptide; CMRI, cardiac magnetic resonance imaging; HF, heart failure;
HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic
peptide; TTE, transthoracic echocardiography39,45,46.
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in patients with HFpEF that were treated with RASs, angioten-
sin-converting enzyme inhibitors, b-blockers58 or sacubitril/val-
sartan59. Although TOPCAT60 showed that spironolactone
treatment reduced the incidence of HHF (HR 0.83, 95% CI
0.69–0.99, P = 0.04) in patinets with HFpEF, it did not reduce
the incidences of total death or hospitalization for any reason.
Furthermore, this treatment was associated with an increase in
serum creatinine concentration and hyperkalemia. Therefore,
the use of mineralocorticoid receptor antagonists has not been
recommended for the treatment of patients with HFpEF. As a
result, a new approach to the diagnosis and treatment of
HFpEF in diabetes has been sought61.
Recently, there have been many studies that show that
SGLT2 inhibitors improve ventricular diastolic function and the
micro- and macrovascular circulation in diabetes patients with
HF. A prospective multicenter study of type 2 diabetes patients
with stable HF was carried out, in which patients with HFpEF
(69%) and HFrEF + HF with midrange EF (31%) were admin-
istered with 5 mg/day dapagliflozin for 6 months. This showed
a significant reduction in the ratio of mitral inflow E to mitral
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Figure 2 | Potential mechanisms for the progression of heart failure. Patients with diabetes can be placed into two categories: those who have
visceral obesity and type 2 diabetes mellitus (T2DM), with multiple coronary risk factors; and those who are lean, and have long-standing, poorly
controlled type 2 or type 1 diabetes mellitus (T1DM). The former category is characterized by the progression of coronary atherosclerosis, resulting
in acute coronary syndrome and severe local perfusion defects, then progression to heart failure with reduced ejection fraction (HFrEF). In addition,
insulin resistance and hyperinsulinemia induce volume overload, resulting in high cardiac preload. Furthermore, insulin resistance and visceral
adiposity are associated with vascular inflammation, endothelial cell dysfunction and a reduction in capillary density, which lead to higher cardiac
afterload and an impairment in left ventricular distension, resulting in the progression of heart failure with preserved ejection fraction (HFpEF). The
latter category comprises patients with prolonged hyperglycemia, and hyperglycemia-induced vascular and cardiac tissue abnormalities, which
impair left ventricular distension and cause the progression of HFpEF. Although HFpEF is considered to be an entirely separate entity to HFrEF as
an etiological background, it is undeniable possibility that HFpEF progresses further into reduced ejection fraction in the advanced stage. Finally,
female and older diabetes patients are more likely to develop HFpEF. The potential sites of sodium–glucose cotransporter 2 (SGLT2) inhibitor action
are shown in green. AGEs, advanced glycation end-products; ECM, extracellular matrix.
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e0 annular velocity (E/e’) from 9.3 to 8.5 cm/s (P < 0.02) in
response to dapagliflozin treatment62. Although this was an
observational, follow-up study without a control group, the
findings suggested that SGLT2 inhibitors might be beneficial
for treatment of left ventricular diastolic dysfunction in dia-
betes. In another study63, empagliflozin was shown to signifi-
cantly reduce diastolic tension, without affecting systolic
function, which was assessed in vitro using ventricular trabecu-
lae isolated from patients with end-stage systolic HF. In addi-
tion, empagliflozin had a beneficial effect to reduce passive
myofilament stiffness by increasing the phosphorylation of
myofilament regulatory proteins.
In CANVAS64, EF was measured by echocardiography as
part of the routine clinical care of the participants, and the inci-
dence of HF was compared between participants with HFpEF
(EF ≥50%) and HFrEF (EF <50%). This analysis showed that
the protective effects of canagliflozin against HF did not signifi-
cantly differ between patients in these two categories and, thus,
provided some hope that HFpEF might be ameliorated by
SGLT2 inhibitor treatment in diabetes patients. Furthermore, in
a subanalysis of the DECLARE-TIMI 58 data65, the ability of
dapagliflozin to prevent CV death and HHF was compared in
participants with low ventricular EF (EF <45%) and those with-
out HFrEF. Of the 17,160 participants, 671 (3.9%) had HFrEF,
1,316 (7.7%) had HF without a known reduction in EF and
15,173 (88.4%) had no history of HF at baseline. The results
showed that dapagliflozin reduced the incidences of CV death
more significantly in patients with HFrEF (HR 0.62, 95% CI
0.45–0.86) than in those without HFrEF (HR 0.88, 95% CI
0.76–1.02). However, it significantly reduced HHF to a similar
extent in patients with (HR 0.64) and without (HR 0.76)
HFrEF. Further clinical trials of the efficacy of SGLT2 inhibitors
for the prevention of cardiovascular events in patients with
HFpEF and HFrEF are now ongoing66–68.
SUBCELLULAR, BIOCHEMICAL AND MOLECULAR
MECHANISMS OF THE BENEFICIAL EFFECTS OF SGLT2
INHIBITORS ON HFPEF IN DIABETES PATIENTS
The molecular mechanisms of the development of HFpEF in
diabetes have been analyzed in a number of studies. The delin-
eation of some of these mechanisms has suggested promising
targets for the amelioration of HFpEF in patients with type 2
diabetes, and below we discuss the subcellular biochemical and
molecular mechanisms whereby SGLT2 inhibitors might pre-
vent HFpEF in diabetes (Figures 3,4).
Effects of SGLT2 inhibitors on nitric oxide production and
oxidative stress
We have reported that insulin resistance is associated with poor
endothelium-dependent vascular relaxation because of impair-
ment in eNOS activity and greater production of the superox-
ide anion69–71. In insulin resistance, eNOS uncoupling is
principally induced by a deficiency of tetrahydrobiopterin (BH4;
an active cofactor of eNOS) in vascular endothelial cells, which
develops because of a reduction in BH4 biosynthesis secondary
to lower activity of guanosine-triphosphate cyclohydrolase I.
Furthermore, 7,8-dihydropteridine (BH2; the inactive form)
concentration markedly increases because of a reduction in the
activity of dihydropteridine reductase, the enzyme that catalyzes
the conversion of BH2 to BH4. The resulting reduction in the
BH4/BH2 ratio significantly reduces eNOS activity and increases
peroxynitrite production in endothelial cells of insulin-resistant
rats (Figure 3). The resulting increase in oxidative stress might
cause higher expression of pro-inflammatory cytokines in car-
diomyocytes. This exposure to pro-inflammatory cytokines and
oxidative stress activates the Janus kinase-signal transduction
and activator of transcription, nuclear factor-kappa B and Smad
signaling pathways in cardiomyocytes72. Interestingly, ipragliflo-
zin administration significantly improves acetylcholine-depen-
dent vasodilation in mice with streptozotocin-induced diabetes,
potentially by ameliorating the impairment of eNOS, and
reducing both reactive oxygen species generation in the
endothelial cells of the abdominal aorta and inflammatory cyto-
kine expression73.
SGLT2 inhibitors reduce pro-inflammatory cytokine secretion
and the activation of downstream signaling pathways
Inflammatory cytokines that are released from hypertrophic
adipocytes activate cytokine signaling in cardiac tissue (the
Janus kinase-signal transduction and activator of transcription,
nuclear factor-kappa B, and Smad signaling pathways; Fig-
ure 3)72,74. Furthermore, transforming growth factor-b is
released by activated macrophages and binds to its receptor on
fibroblasts in cardiac tissue, which activates Smad signaling,
resulting in greater synthesis of extracellular matrix proteins74.
Hyperglycemia-induced cardiac damage is also caused by an
increase in reactive oxygen species, inflammation and apopto-
sis75,76. Furthermore, it has been shown that greater release of
pro-inflammatory cytokines by hypertrophic adipocytes stimu-
lates the expression of inducible NOS in cardiomyocytes sec-
ondary to the activation of nuclear factor-kappa B77,78. Thus,
the oxidative stress that is induced by insulin resistance and
hyperglycemia activates inflammatory cytokine signaling in car-
diomyocytes.
Interestingly, the SGLT2 inhibitor ipragliflozin ameliorates
diabetes and obesity-associated metabolic abnormalities in
type 2 diabetes mice79. In addition, 8 weeks of empagliflozin
treatment significantly improves diabetic myocardial structure
and function, and ameliorates fibrosis through inhibition of the
transforming growth factor-b/Smad signaling pathway in dia-
betic KK-Ay mice80. Furthermore, canagliflozin is superior to
glimepiride with respect to its beneficial effects on adipose tis-
sue function and serum leptin, adiponectin, and interleukin-6
concentrations, which are related to the reduction in CV risk81.
Recently, further interesting work regarding the molecular
mechanisms of the progression of HFpEF has been published82.
Overexpression of nitric oxide synthase (iNOS) induces reduc-
tions in the activities of two proteins: an isoform of X-box
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binding protein 1 (XBP1) and inositol-requiring enzyme 1a.
Inositol-requiring enzyme 1a is responsible for the splicing of
XBP1 messenger ribonucleic acid to yield XBP1s, and only this
spliced form of XBP1 can efficiently activate the unfolded pro-
tein response. Thus, a reduction in XBP1s expression inhibits
the unfolded protein response, which causes the myocardial
accumulation of destabilized proteins and greater apoptosis of
cardiomyocytes82. In fact, Schiattarella et al. induced HFpEF in
mice by feeding a high-fat diet, which involved the cardiac acti-
vation of iNOS, causing inflammation, and successfully induced
hypertension with the use of Nx-nitro-L-arginine methyl ester,
an inhibitor of eNOS. In addition, they also showed that a defi-
ciency in iNOS expression or overexpression of XBP1s amelio-





















































Figure 3 | Oxidative stress and effects of inflammatory cytokines in the cardiac tissue in obese type 2 diabetes patients and the sites of sodium–
glucose cotransporter 2 (SGLT2) inhibitor action. Systemic low-grade inflammation is a characteristic of patients with visceral obesity and insulin
resistance. Plasma inflammatory cytokine concentrations are high in these patients, and activate intracellular cytokine signaling in cardiomyocytes.
Impaired activation of endothelial nitric oxide synthase (eNOS) and higher nicotinamide dinucleotide phosphate (NADPH) oxidase activity in
endothelial cells are also characteristics of patients with insulin resistance. Oxidative stress in cardiac tissues also induces intracellular inflammatory
cytokine signaling in cardiomyocytes, which results in higher nitric oxide synthase (iNOS) expression, cell death, accumulation of extracellular matrix
(ECM) proteins, and an increase in the rigidity of proteins in cardiac muscle cells. Furthermore, systemic inflammation and the activation of
endothelial cells stimulates monocyte infiltration and transformation into macrophages. Activated macrophages produce transforming growth
factor-b (TGF-b), which in turn activates myofibroblast infiltration and ECM overproduction. All these molecular mechanisms increase diastolic left
ventricular stiffness, predisposing toward heart failure with preserved ejection fraction (HFpEF). The possible sites of SGLT2 inhibitor action are
shown in green. Red arrows: ↑ increase, ↓ decrease. BH2, 7,8-dihydropteridine; BH4, tetrahydrobiopterin; eNOS, endothelial nitric oxide synthase; IL-6,
interleukin-6; JAK-STAT, Janus kinase-signal transduction and activator of transcription; MCP-1, monocyte chemotactic protein-1; NADPH,
nicotinamide dinucleotide phosphate; NADPHox, nicotinamide dinucleotide phosphate oxidase; NF-jB, nuclear factor-kappa B; NO, nitric oxide; PKG,
cyclic GMP-dependent protein kinase G; sGC, soluble guanylate cyclase; TNF-a, tumor necrosis factor-a; UPR, unfolded protein response; XBP1s,
spliced form of X-box binding protein 1.
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associated with lower left ventricular filling pressure and less
pulmonary congestion83. Furthermore, inflammatory cytokines
inhibit eNOS production, and reduce the activities of both sol-
uble guanylate cyclase and protein kinase G in endothelial cells,
which reduces the phosphorylation of titin84, and overproduc-
tion of reactive oxygen might cause disulfide bonds to be estab-
lished in titin molecules. Both of these changes alter the rigidity
of titin, and lead to cardiac muscle stiffening. Therefore, SGLT2
inhibitors might be able to inhibit iNOS expression and activate
eNOS, causing an increase in XBP1s expression and greater
titin phosphorylation in cardiac muscle63. This possibility is fur-
ther tested in animal models of diabetes in future studies.
Clinical significance of the inhibition of Na+-H+ exchanger 1 in
the diabetic myocardium by SGLT2 inhibitor treatment
The Na+-H+ exchanger (NHE1; the predominant isoform of
NHE in cardiomyocytes) plays an important role in maintain-
ing intracellular pH during myocardial ischemia, when the high
intracellular H+ concentration activates NHE1, which reduces



























































Figure 4 | Sodium–glucose cotransporter 2 (SGLT2) inhibitors inhibit Na+-H+ exchanger 1 (NHE1) and increase ketone body production, which
ameliorate cardiac dysfunction in type 2 diabetes. The NHE1 is directly inhibited by SGLT2 inhibitors. The activation of NHE1 increases cytosolic
[Na+] and [Ca2+], and reduces mitochondrial [C2+]. These ionic derangements result in impaired efficiency of mitochondrial adenosine triphosphate
(ATP) production, Ca2+ overload and cell death. Treatment with SGLT2 inhibitors ameliorates these abnormalities in intracellular ion concentrations.
Plasma ketone body concentrations are high in diabetes patients because of insulin deficiency, higher counter-regulatory hormone activity and a
deficiency in dietary carbohydrate intake. Although ketone body production in diabetes is high in both the fasting and postprandial states, SGLT2
inhibitors also increase serum ketone concentrations. Red arrows: ↑ increase, ↓ decrease. b-HB, b-hydroxybutyrate; AcAc CoA, acetoacetyl
coenzyme A; AcAc, acetoacetate; MCT, monocarboxylate transporter; NCX, Na+-Ca2+ exchanger; VDCC, voltage-dependent calcium channel.
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the Na+-Ca2+ exchanger, leading to an increase in cytosolic
[Ca2+]85.
Interestingly, it has been reported that SGLT2 inhibitors
might directly inhibit NHE1 in the myocardium (Figure 4)86.
Dapagliflozin reduces the amplitude of cell shortening and the
L-type Ca2+ current in ventricular cardiomyocytes from strepto-
zotocin-treated rats, which implies that SGLT2 inhibitors have
an acute negative inotropic effect in diabetic cardiomyocytes87.
Consistent with this, empagliflozin reduces both cytosolic [Na+]
and [Ca2+] during both systole and diastole, and increases
mitochondrial [Ca2+] in rat cardiomyocytes88. These findings
might reflect a greater mitochondrial capacity to synthesize ade-
nosine triphosphate (ATP), restoring the energetic state of car-
diomyocytes (Figure 4). Both dapagliflozin and canagliflozin
also inhibit NHE1, and reduce cytosolic [Na+] in mouse car-
diomyocytes and hearts89. Interestingly, SGLT2 inhibitors have
high binding affinities for the extracellular Na+-binding site of
NHE89. These data show that SGLT2 inhibitors might have an
off-target effect on NHE1. In addition, it has been suggested
that SGLT2 inhibitors promote natriuresis by inhibiting NHE3
activity in the proximal tubule90, which might represent an
additional mechanism by which they reduce the incidence of
HHF in diabetes patients.
Role of ketone bodies in amelioration of the cardiac energy
crisis in diabetes patients with a failing heart by SGLT2
inhibitor treatment
Diabetes patients with cardiomyopathy and a failing heart often
develop a cardiac energy crisis. Therefore, interventions that
improve cardiac energy metabolism might be effective treat-
ments for cardiac dysfunction in patients with diabetes. It is
generally accepted that glucose utilization is significantly
impaired in the diabetic heart, and ATP generation in car-
diomyocytes is highly dependent on free fatty acid metabolism,
which can adversely affect cardiomyocytes91. Furthermore, it
has been reported that the myocardial uptake of glucose, lactate
and pyruvate are lower, whereas that of ketone bodies is higher
in individuals with diabetes than non-diabetic individuals92.
The use of ketone bodies is more energetically efficient than
fatty acid oxidation, because it yields more energy for ATP syn-
thesis per molecule of oxygen93. Furthermore, the use of ketone
bodies is associated with less mitochondrial uncoupling and
oxidative stress94–96. During the development of cardiac hyper-
trophy and HF in mouse models, ketone oxidation increases in
the heart, and ketone bodies become a key fuel source in the
context of a lower capacity to oxidize fatty acids97. A vast
quantity of evidence shows that the hepatic rate of ketogenesis
is finely regulated by an orchestrated series of metabolic inter-
actions between adipose tissue and the liver (Figure 4). Plasma
ketone body concentrations increase in patients with diabetes
treated with SGLT2 inhibitors because of greater ketogenesis in
the liver and an increase in renal tubular reabsorption of ketone
bodies98,99. In this way, SGLT2 inhibitors increase circulating
ketone body concentrations100–102. Therefore, the effect of
SGLT2 inhibitors to prevent HHF might be partly attributable
to increases in plasma ketone body concentrations. Interest-
ingly, a 3-h infusion of 3-hydroxybutyrate increased the plasma
concentration of this ketone from 0.4 to 3.3 mmol/L
(P < 0.001), which was accompanied by an 8% increase in car-
diac output (P < 0.001). Furthermore, there was a dose-depen-
dent relationship between the increase in plasma 3-
hydroxybutyrate and cardiac output103. Therefore, therapeutic
approaches aimed at increasing circulating ketone body concen-
trations in HF patients are currently under investigation in pre-
clinical and clinical studies.
CONCLUSION
SGLT2 inhibitors effectively protect against major adverse car-
diovascular events, especially in type 2 diabetes patients with a
previous history of atherosclerotic cardiovascular disease and
advanced renal disease. Furthermore, similar reductions in both
HHP and RCOs occur in type 2 diabetes patients, regardless of
the level of cardiorenal risks. HF is a major clinical problem that
determines the life expectancy of diabetes patients. One particu-
lar challenge is to protect diabetes patients against the develop-
ment of HFpEF and HErEF. HFpEF is clinically characterized
by diastolic dysfunction, which is highly prevalent in diabetes
patients with multiple CV risks. It is generally accepted that
SGLT2 inhibitors ameliorate visceral adiposity, insulin resistance,
hyperglycemia, hyperlipidemia, volume overload and hyperten-
sion. Furthermore, it has also been suggested that SGLT2 inhibi-
tor treatment ameliorates endothelial dysfunction, inflammatory
cytokine signaling, the inhibition of Ca2+ overload as a result of
the inhibition of NHE1 activity and mitochondrial dysfunction;
and increases serum ketone body concentrations, which have
been shown to ameliorate HFpEF in preclinical and clinical
studies. In summary, we suggest that the use of SGLT2 inhibi-
tors represents an effective new approach for the prevention of
HFpEF in patients with diabetes.
ACKNOWLEDGMENTS
We thank Mark Cleasby, PhD, from Edanz Group (www.eda
nzediting.com/ac) for editing drafts of this manuscript.
DISCLOSURE
AK is a consultant for and has received consulting fees from
the Sunstar group. HM has received lecture fees from MSD
K.K., Nippon Boehringer Ingelheim Co. Ltd., Astellas Pharma
Inc., Mitsubishi-Tanabe Pharma Corporation, Sanofi K.K.,
Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd.,
AstraZeneca K.K., Novo Nordisk Pharma Ltd., Sumitomo
Dainippon Pharma Co. Ltd. and Eli Lilly; research support
from Astellas Pharma Inc., AstraZeneca K.K., Nippon Boehrin-
ger Ingelheim Co. Ltd., Sunstar Inc., Mitsubishi Tanabe Pharma
Corporation, Kyowa Kirin Co. Ltd., Nissan Chemical Corpora-
tion and MIKI Corporation; and research grants from Takeda
Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD K.K., Nip-
pon Boehringer Ingelheim Co. Ltd., Kyowa Kirin Co. Ltd.,
ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol.  No.   2020 11
R E V I EW A R T I C L E
http://wileyonlinelibrary.com/journal/jdi SGLT2 inhibitors for heart failure prevention
Taisho-Toyama Pharm Co. Ltd., Kowa Pharmaceutical Co.
Ltd., Ono Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd.,
Sanofi K.K., Mitsubishi-Tanabe Pharma Corporation, Sanwa
Kagaku Kenkyusho Co. Ltd., Eli Lilly Japan K.K., Sumitomo
Dainippon Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Bayer
Yakuhin Ltd., Teijin Ohama Co. Ltd., Novartis Pharma K.K.
and Nipro Corporation. SA has received lecture fees from
Kyowa Kirin Co. Ltd. and Mitsubishi Tanabe Pharma Corpora-
tion; and research grants from Kyowa Kirin Co. Ltd., Daiichi
Sankyo Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd., Chu-
gai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd.,
Torii Pharmaceutical Co. Ltd., Sanofi K.K., MSD K.K. and JCR
pharmaceuticals Co. Ltd.
REFERENCES
1. Lee WS, Kanai Y, Wells RG, et al. The high affinity Na+/
glucose cotransporter. J Biol Chem 1994; 269: 12032–12039.
2. Wright EM, Loo DD, Hirayama BA. Biology of human
sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
3. Bailey CJ. Renal glucose reabsorption inhibitors to treat
diabetes. Trends Pharmacol Sci 2011; 32: 63–71.
4. Abdul-Ghani M, DeFronzo R, Norton L. Novel hypothesis to
explain why SGLT2 inhibitors inhibit only 30–50% of
filtered glucose load in humans. Diabetes 2013; 62: 3324–
3328.
5. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic
response to sodium-glucose cotransporter 2 inhibition in
type 2 diabetic patients. J Clin Invest 2013; 124: 499–508.
6. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin
improves muscle insulin sensitivity but enhances
endogenous glucose production. J Clin Invest 2014; 124:
509–514.
7. Cefalu WT. Paradoxical insights into whole body metabolic
adaptations following SGLT2 inhibition. J Clin Invest 2015;
124: 485–487.
8. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium
glucose co- transporter 2 inhibitor, improves model-based
indices of beta cell function in patients with type 2
diabetes. Diabetologia 2014; 57: 891–901.
9. Rossetti L, Smith D, Shulman GI, et al. Correction of
hyperglycemia with phlorizin normalizes tissue sensitivity to
insulin. J Clin Invest 1987; 79: 1510–1515.
10. Takahara M, Shiraiwa T, Matsuoka T, et al. Ameliorated
pancreatic b cell dysfunction in type 2 diabetic patients
treated with a sodium-glucose cotransporter 2 inhibitor
ipragliflozin. Endocrine J 2015; 62: 77–86.
11. Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on
liver function tests in patients with type 2 diabetes.
Diabetes Metab 2016; 42: 25–32.
12. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the
glucose transporter SGLT2 with dapagliflozin in pancreatic
alpha cells triggers glucagon secretion. Nat Med 2015; 21:
512–517.
13. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers
serum uric acid through alteration of uric acid transport
activity in renal tubule by increased glycosuria. Biopharm
Drug Dispos 2014; 35: 391–404.
14. Oliva RV, Bakris GL. Blood pressure effects of sodium-
glucose-cotransport 2 (SGLT2) inhibitors. J Am Soc
Hypertens 2014; 8: 330–339.
15. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces
blood pressure in patients with type 2 diabetes and
hypertension. Diabetes Care 2015; 38: 420–428.
16. Kashiwagi A, Yoshida S, Kawamura K, et al. Effects of
ipragliflozin, a selective sodium–glucose co-transporter 2
inhibitor, on blood pressure in Japanese patients with
type 2 diabetes mellitus: a pooled analysis of six
randomized, placebo-controlled clinical trials. Diabetol Int
2017; 8: 76–86.
17. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-
glucose co-transporter 2 inhibitors on blood pressure: a
systematic review and meta-analysis. J Am Soc Hypertens
2014; 8: 262–275.
18. Sha S, Polidori D, Heise T, et al. Effect of the sodium
glucose co-transporter 2 inhibitor canagliflozin on plasma
volume in patients with type 2 diabetes mellitus. Diabetes
Obes Metab 2014; 16: 1087–1095.
19. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of
dapagliflozin on body weight, total fat mass, and regional
adipose tissue distribution in patients with type 2 diabetes
mellitus with inadequate glycemic control on metformin. J
Clin Endocrinol Metab 2012; 97: 1020–1031.
20. Kashiwagi A, Maegawa H. Metabolic and hemodynamic
effects of sodium dependent glucose cotransporter 2
inhibitors on cardio-renal protection in the treatment of
patients with type 2 diabetes mellitus. J Diabetes Investig
2017; 8: 416–427.
21. Kashiwagi A, Sakatani T, Nakamura I, et al. Improved
cardiometabolic risk factors in Japanese patients with type
2 diabetes treated with ipragliflozin: a pooled analysis of
six randomized, placebo-controlled trials. Endocrine J 2018;
65: 691–705.
22. Zimman B, Wanner C, Lachin JM, et al. EMPA-REG
OUTCOME Investigators. Empagliflozin, cardiovascular
outcomes and mortality in type 2 diabetes. N Engl J Med
2015; 373: 2117–2128.
23. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
progression of kidney disease in type 2 diabetes. N Engl J
Med 2016; 375: 323–334.
24. Cherney DZ, Zinman B, Inzucchi SE, et al. OUTCOME
Investigators. Effects of empagliflozin on the urinary
albumin-to-creatinine ratio in patients with type 2 diabetes
and established cardiovascular disease: and exploratory
analysis from the EMPA-REG OUTCOME randomized,
placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5:
610–621.
12 J Diabetes Investig Vol.  No.   2020 ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
R E V I EW A R T I C L E
Kashiwagi et al. http://wileyonlinelibrary.com/journal/jdi
25. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and
cardiovascular and renal events in type 2 diabetes. N Engl J
Med 2017; 377: 644–657.
26. Wiviott SD, Bonaca MP, Mosenzon O, et al. Dapagliflozin
and cardiovascular outcomes in type 2 diabetes. N Engl J
Med 2019; 380: 347–357.
27. Perkovic V, Jardine MJ, Neal S, et al. Canagliflozin and renal
outcomes in type 2 diabetes and nephropathy. N Engl J
Med 2019; 380: 2295–2306.
28. Marso SP, Daniels GH, Brown-Frandson K, et al. Liraglutide
and cardiovascular outcomes in type 2 diabetes. New Engl
J Med 2016; 375: 311–322.
29. Marso SP, Bain SC, Consoli A, et al. Semaglutide and
cardiovascular outcomes in patients with type 2 diabetes.
New Engl J Med 2016; 375: 1834–1844.
30. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-
weekly exenatide on cardiovascular outcomes in type 2
diabetes. New Engl J Med 2017; 377: 1228–1239.
31. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide
and renal outcomes in type 2 diabetes. N Engl J Med 2017;
377: 839–848.
32. Cosentio F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines
on diabetes, pre-diabetes, and cardiovascular diseases
developed in collaboration with EASD. Eur Heart J 2020; 41:
255–323.
33. Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2
inhibitors on cardiorenal outcomes. Cardiovasc Diabetol
2019; 18: 99.
34. Rabizadeh S, Nakhjavani M, Esteghmati A. Cardiovascular
and renal benefits of SGLT2 inhibitors: a narrative review.
Int J Endocrinol Metab 2019; 17: e84353.
35. Verma S, McMurray JJV. SGLT2 inhibitor and mechanisms
of cardiovascular benefit: a state -of-the-art review.
Diabetologia 2018; 61: 2108–2117.
36. Cavender MA, Norhammar A, Birkeland KI, et al. SGLT2
inhibitors and cardiovascular risk: an analysis of CVD-REAL. J
Am Coll Cardiol 2018; 71: 2497–2506.
37. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular
events associated with SGLT2 inhibitors versus other
glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll
Cardiol 2018; 71: 2628–2639.
38. Heerspink HL, Karasik A, Thuresson M, et al. Kidney
outcomes associated with use of SGLT2 inhibitors in real
world clinical practice (CVD-REAL 3): a multinational
observational cohort study. Lancet Diabetes Endocrinol 2020;
8: 27–35.
39. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guideline
for the diagnosis and treatment of acute and chronic heart
failure: the task force for the diagnosis and treatment of
acute and chronic heart failure of the European Society of
cardiology (ESC). Eur Heart J 2016; 37: 2129–2200.
40. Bell DSH. Heart failure: the frequent, forgotten, and often
fetal complication of diabetes. Diabetes Care 2003; 26:
2433–2441.
41. Nichols GA, Ephross SA, Gullion CM, et al. The incidence of
congestive heart failure in type 2 diabetes: an update.
Diabetes Care 2004; 27: 1879–1884.
42. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of
cardiomyopathy associated with diabetic
glomerulosclerosis. Am J Cardiol 1972; 30: 595–602.
43. Bell DSH. Diabetic cardiomyopathy. Diabetes Care 2003; 26:
2949–2951.
44. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy:
a two-faced disease with restrictive and dilated
phenotypes. Eur Heart J 2015; 36: 1718–1727.
45. Shah S, Katz DH, Deo RC. Phenotypic spectrum of heart
failure with preserved ejection fraction. Heart Fail Clin 2014;
10: 407–418.
46. Clarke GD, Molina-Wilkins M, Solis-Herrera C, et al. Impaired
left ventricular diastolic function in T2DM patients is closely
related to glycemic control. Endocrine Diab Metab 2018; 1:
e00014.
47. Triposkiadis F, Giamouzis G, Parrissis J, et al. Reframing the
association and significance of co-morbidities in heart
failure. Eur J Heart Fail 2016; 18: 744–58.
48. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of
candesartan in patients with chronic heart failure and
reduced left-ventricular systolic function taking angiotensin-
converting-enzyme inhibitors: the CHARM-Added Trial.
Lancet 2003; 362: 767–771.
49. Sandesara PB, O’Neal WT, Kelli HM, et al. The prognostic
significance of diabetes and microvascular complications in
patients with heart failure with preserved ejection fraction.
Diabetes Care 2018; 41: 150–155.
50. Tromp J, Lim SL, Toy WT, et al. Microvascular disease in
patients with diabetes with reduced ejection fraction
versus preserved ejection fraction. Diabetes Care 2019; 42:
1792–1799.
51. Packer M, Kitzman DW. Obesity-related heart failure with a
preserved ejection fraction: the mechanistic rationale for
combining inhibitors of aldosterone, neprilysin, and
sodium-glucose cotransporter-2. J Am Coll Cardiol 2018; 6:
633–639.
52. Bakker W, Eringa EC, Sipkema P, et al. Endothelial
dysfunction and diabetes: roles of hyperglycemia, impaired
insulin signaling and obesity. Cell Tissue Res 2009; 335: 165–
189.
53. Sorop O, Heinonen I, van Kranenburg M, et al. Multiple
common comorbidities produce left ventricular diastolic
dysfunction associated with coronary microvascular
dysfunction, oxidative stress, and myocardial stiffening.
Cardiovasc Res 2018; 114: 954–964.
54. Patel VB, Shah S, Verma S, et al. Epicardial adipose tissue as
a metabolic transducer: role in heart failure and coronary
artery disease. Heart Fail Rev 2007; 22: 889–902.
55. Pitt B, Zannad F, Remme WJ, et al. The effect of
spironolactone on morbidity and mortality in patients with
severe heart failure. N Engl J Med 1999; 341: 709–717.
ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol.  No.   2020 13
R E V I EW A R T I C L E
http://wileyonlinelibrary.com/journal/jdi SGLT2 inhibitors for heart failure prevention
56. Solomon SD, Claggett B, McMurray JJV, et al. Combined
neprilysin and renin-angiotensin system inhibition in heart
failure with reduced ejection fraction: a meta-analysis. Eur J
Heart Fail 2016; 18: 1238–1243.
57. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin
in patients with heart failure and reduced ejection fraction.
N Engl J Med 2019; 381: 1995–2008.
58. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology
and clinical course of heart failure with preserved ejection
fraction. Eur J Heart Fail 2011; 13: 18–28.
59. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–
neprilysin inhibition in heart failure with preserved ejection
fraction. N Engl J Med 2019; 381: 1609–1620.
60. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for
heart failure with preserved ejection fraction. N Engl J Med
2014; 370: 1383–1392.
61. Kashiwagi A. A new door opens, but it is essential to
accumulate further clinical evidence to control heart failure
in diabetes with preserved ejection fraction. J Diabetes
Investig 2019; 10: 1145–1147.
62. Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin
on left ventricular diastolic function of patients with type 2
diabetic mellitus with chronic heart failure. Cardiovasc
Diabetol 2018; 17: 132–140.
63. Pabel S, Wagner S, Bollenberg H, et al. Empagliflozin
directly improves diastolic function in human heart failure.
Eur J Heart Fail 2018; 20: 1690–1700.
64. Figtree GA, Radholm K, Barrett TD, et al. Effects of
canagliflozin on heart failure outcomes associated with
preserved and reduced ejection fraction in type 2 diabetes
mellitus: results from the CAVAS program. Circulation 2019;
139: 2591–2593.
65. Kato ET, Silverman MG, Mosenzon O, et al. Effect of
dapagliflozin on heart failure and mortality in type 2
diabetes mellitus. Circulation 2019; 139: 2528–2536.
66. Milton Packer M, Butler J, Filippatos GS, et al. Evaluation of
the effect of sodium glucose co-transporter 2 inhibition
with empagliflozin on morbidity and mortality of patients
with chronic heart failure and a reduced ejection fraction:
rationale for and design of the EMPEROR-Reduced Trial. Eur
J Heart Fail 2019; 21: 1270–1278.
67. Anker SD, Butler J, Filippatos GS, et al. Evaluation of the
effects of sodium-glucose cotransporter 2 inhibition with
empagliflozin on morbidity and mortality in patients with
chronic heart failure and a preserved ejection fraction:
rationale for and design of the EMPEROR-Preserved Trial.
Eur J Heart Fail 2019; 21: 1279–1287.
68. Jensen J, Omar M, Kistorp C, et al. Empagliflozin in
heart failure patients with reduced ejection fraction:
a randomized clinical trial (Empire HF). Trials 2019;
20: 374.
69. Shinozaki K, Kashiwagi A, Nishio Y, et al. Abnormal
biopterin metabolism is a major cause of impaired
endothelial-dependent relaxation through nitric oxide/O2
-
imbalance in insulin-resistant rat aorta. Diabetes 1999; 48:
2437–2445.
70. Kashiwagi A, Shibozaki K, Nishio Y, et al. Free radical
production in endothelial cells as a pathogenetic factor for
vascular dysfunction in the insulin-resistance state. Diabetes
Res Clin Pract 1999; 45: 199–203.
71. Shinozaki K, Hirayama A, Nishio Y, et al. Coronary
endothelial dysfunction in the insulin-resistant state is
linked to abnormal pteridine metabolism and vascular
oxidative stress. J Am Coll Cardiol 2001; 38: 1821–1828.
72. Aoyagi T, Matsui T. The cardiomyocytes as a source of
cytokines in cardiac injury. J Cell Sci Ther 2011.
https://doi.org/10.4172/2157-7013.S5-003
73. Salim HM, Fukuda D, Yagi S, et al. Gylcemic control with
ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated
endothelial dysfunction in streptozotocin-induced diabetic
mouse. Front Cardiovasc Med 2016; 3: 1–9.
74. Sprague AH, Khalil RA. Inflammatory cytokines in vascular
dysfunction and vascular disease. Biochem Pharmacol 2009;
15: 539–552.
75. Palomer X, Salvado L, Barroso E, et al. An overview of the
crosstalk between inflammatory processes and metabolic
dysregulation during diabetic cardiomyopathy. Int J Cardiol
2013; 168: 3160–3172.
76. Ansley DM, Wang B. Oxidative stress and myocardial injury
in the diabetic heart”. J Pathol 2013; 229: 232–241.
77. Balligand J-L, Ungureanu-Longrois D, Simmons WW, et al.
Cytokine-inducible nitric oxide synthase (iNOS) expression
in cardiac myocytes: characterization and regulation of
iNOS expression and detection of iNOS activity in single
cardiac myocytes in vitro. J Biol Chem 1994; 269: 27580–
27588.
78. Liu T, Zhang L, Joo D, et al. NF-kB signaling in
inflammation. Signal Transduct Target Ther 2017; 2: 17023.
79. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2
selective inhibitor ipragliflozin on hyperglycemia,
hyperlipidemia, hepatic steatosis, oxidative stress,
inflammation, and obesity in type 2 diabetic mice. Eur J
Pharmacol 2013; 715: 246–255.
80. Li C, Zhang J, Xue M, et al. SGLT2 inhibition with
empagliflozin attenuates myocardial oxidative stress and
fibrosis in diabetic heart. Cardiovasc Diabetol 2019; 18: 15.
81. Garvey WT, Gaal LV, Leiter LA, et al. Effects of canagliflozin
versus glimepiride on adipokines and inflammatory
biomarkers in type 2 diabetes. Metabolism 2018; 85: 32–37.
82. Paulus WJ. Unfolding discoveries in heart failure. New Engl
J Med 2020; 382: 679–682.
83. Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative
stress drives heart failure with preserved ejection fraction.
Nature 2019; 568: 351–356.
84. Franssen C, Chen S, Unger A, et al. Myocardial
microvascular inflammatory endothelial activation in heart
failure with preserved ejection fraction. J Am Coll Cardiol
Heart Fail 2016; 4: 312–24.
14 J Diabetes Investig Vol.  No.   2020 ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
R E V I EW A R T I C L E
Kashiwagi et al. http://wileyonlinelibrary.com/journal/jdi
85. Karmazyn M, Gan XT, Humphreys RA, et al. The myocardial
Na+-H+ exchange; structure, regulation, and role in heart
disease. Circ Res 1999; 85: 777–786.
86. Packer M, Anker SD, Butler J, et al. Effects of sodium-
glucose cotransporter 2 inhibitors for the treatment of
patients with heart failure: proposal of a novel mechanism
of action. JAMA Cardiol 2017; 2: 1025–1029.
87. Hamouda NN, Sydorenko V, Qureshi MA, et al.
Dapagliflozin reduces the amplitude of shortening and
Ca2+ transient in ventricular myocytes from streptozotocin-
induced diabetic rats. Mol Cell Biochem 2014; 400: 57–68.
88. Baartscheer A, Schumacher CA, Wust RCI, et al.
Empagliflozin decreases myocardial cytoplasmic Na+
through inhibition of the cardiac Na+/H+ exchanger in rats
and rabbits. Diabetologia 2017; 60: 568–573.
89. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of
SGLT2 inhibitors in mouse cardiomyocytes and hearts;
inhibition of Na+/H+ exchange, lowering of cytosolic Na+
and vasodilation. Diabetologia 2018; 61: 722–726.
90. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a
therapeutic target for diabetes: basic physiology and
consequences. Diab Vasc Dis Res 2015; 12: 78–89.
91. Goldberg IJ, Trent CM, Schulze C. Lipid metabolism and
toxicity in the heart. Cell Metab 2012; 15: 805–812.
92. Mizuno Y, Harada E, Nakagawa H, et al. The diabetic heart
utilizes ketone bodies as an energy source. Metabolism
2017; 77: 65–72.
93. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies,
and mitochondrial energy transduction. FASEB J 1995; 9: 651–
658.
94. Shimazu T, Hirschey MD, Newman J, et al. Suppression of
oxidative stress by b-hydroxybutyrate, an endogenous
histone decarboxylase inhibitor. Science 2013; 339: 211–214.
95. Kolwicz SC, Airhart S, Tian R, et al. Ketones step to the
plate: a game changer for metabolic remodeling in heart
failure? Circulation 2016; 133: 689–691.
96. Ferrannini E, Mark M, Mayoux E, et al. CV protection in the
EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis.
Diabetes Care 2016; 39: 1108–1114.
97. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies
on ketone bodies as a fuel. Circulation 2016; 133: 698–705.
98. Pachalska P, Crawford PA. Multi-dimensional roles of
ketone bodies in fuel metabolism, signaling, and
therapeutics. Cell Metab 2017; 25: 262–284.
99. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may
predispose to ketoacidosis. J Clin Endocrinol Metab 2015;
100: 2849–2852.
100. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate
utilization in response to sodium-glucose cotransporter 2
inhibition in subjects without diabetes and patients with
type 2 diabetes. Diabetes 2016; 65: 1190–1195.
101. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel
energetics explain the beneficial cardiorenal outcomes in
the EMPA-REG OUTCOME study? A unifying hypothesis.
Diabetes Care 2016; 39: 1115–1122.
102. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of
monotherapy with the novel sodium/glucose
cotransporter-2 inhibitor tofogliflozin in Japanese patients
with type 2 diabetes mellitus: a combined Phase 2 and 3
randomized, placebo-controlled, double-blind, parallel-
group comparative study. Cardiovasc Diabetol 2014; 13:
65–80.
103. Nielsen R, Moller N, Gormsen LC, et al. Cardiovascular
effects of treatment with ketone body 3-hydroxybutyrate
in chronic heart failure patients. Circulation 2019; 139:
2129–2141.
ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol.  No.   2020 15
R E V I EW A R T I C L E
http://wileyonlinelibrary.com/journal/jdi SGLT2 inhibitors for heart failure prevention
